预约演示
更新于：2025-07-09
Mecobalamin
甲钴胺
更新于：2025-07-09
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1987-04-16), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C63H91CoN13O14P |
InChIKeyROWAQRTUUUIVDZ-FGIXMQGJSA-M |
CAS号13422-55-4 |
关联
62
项与 甲钴胺 相关的临床试验NCT06813274
Multicenter, Double Blind, Randomized, Placebo-controlled Trial to Exploring the Role of Eye-Brain Multimodal Imaging in Diagnosing and Treating Neurovascular Coupling Impairment in Diabetes Mellitus
CTRI/2024/10/075367
A prospective, open-label, randomized, comparative clinical trial to assess theefficacy and safety of a novel Methylcobalamin Nasal Spray (NASO B12) or oral B12 supplementation in the treatment of subjects with vitamin B12 deficiencyas well as to evaluate the duration of efficacy - Nill
CTRI/2024/10/074789
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, oral bioequivalence studyof Pregabalin (PR), Methylcobalamin and Nortriptyline Hydrochloride Tablets (75 mg+1500 mcg+10 mg) of Unison Pharmaceuticals Private Limited with NeuGaba® MN Tablets [Pregabalin (PR), Methylcobalamin and Nortriptyline Hydrochloride Tablets (75 mg+1500 mcg+10mg)] Manufactured By: Synokem Pharmaceuticals Limited; Marketed By: Sun Pharma Laboratories Limited in healthy adult human subjects under fasting conditions. - NIL
100 项与 甲钴胺 相关的临床结果
登录后查看更多信息
100 项与 甲钴胺 相关的转化医学
登录后查看更多信息
100 项与 甲钴胺 相关的专利（医药）
登录后查看更多信息
2,116
项与 甲钴胺 相关的文献（医药）2025-06-23Scientific Reports
Green and white analytical approach for parallel quantification of gabapentin and methylcobalamin in medicinal products using inventive RP-HPLC technique.
Article
作者: Mohamed, Mahmoud A ; Binsaleh, Ammena Y ; Saleh, Sayed M ; Alminderej, Fahad M ; Alsehli, Bandar R ; Mahgoub, Samar M
A simple, selective, and environmentally sustainable RP-HPLC method was developed for simultaneous quantification of gabapentin (GAB) and Methylcobalamin (MET) in pharmaceutical products. Separation was achieved on a Zorbax Eclipse C8 column (150 × 4.6 mm, 3.5 μm) using a green mobile phase of potassium phosphate buffer (pH 6.9)/acetonitrile (95:5 v/v) at 2.0 mL/min, with detection at 210 nm. Total analysis time was 10 min with 100 µL injection volume. The method showed excellent linearity (3-50 µg/mL; R² > 0.9998), LODs (0.60-0.80 µg/mL), and LOQs (2.00-2.50 µg/mL). Environmental sustainability was validated by multiple metrics: AGREE (0.70), AGREEprep (0.71), and Analytical Eco-Scale (80), confirming superior greenness. Forced degradation studies demonstrated stability-indicating capability per ICH guidelines. This eco-friendly approach provides a reliable solution for quality control of GAB/MET formulations while minimizing environmental impact.
2025-05-09MEDICINE
Drug-induced hypesthesia due to dexamethasone: A case report
Article
作者: Yang, Bo ; Jia, WenHao
Rationale::
Systemic glucocorticoids are widely used in the treatment of various inflammatory and autoimmune conditions. This report describes the first known case of drug-induced hypesthesia following dexamethasone administration in a patient without prior neurological conditions.
Patient concerns::
A 38-year-old female patient presented with bothersome and intolerable tinnitus and was diagnosed with sudden sensorineural hearing loss. She was treated with dexamethasone (10 mg IVGTT once daily) for 6 days. On the 5th day of treatment, the patient began experiencing fatigue, followed by decreased sensitivity to pain, temperature, and touch, anhidrosis, and lack of satiety.
Diagnoses::
Drug-induced hypesthesia.
Interventions::
Dexamethasone was discontinued after completing the 6-day treatment course. The patient was then prescribed omeprazole and mecobalamin for supportive care.
Outcomes::
The patient’s sensory impairment began to resolve 3 days after stopping dexamethasone. Follow-up 1 week later confirmed complete recovery without recurrence of hypesthesia.
Lessons::
This case highlights the importance of monitoring patients for hypesthesia during dexamethasone therapy, even in the short term. Clinicians should be aware of this potential adverse effect and consider alternative treatments if necessary. Mecobalamin may be a supportive option for managing hypesthesia in such cases.
2025-05-01Cancer Reports
Complete Immunophenotypic Reversal of Chronic Lymphocytic Leukaemia With High Dose Parenteral Methylcobalamin: A Case Report and Brief Review of Cobalamin in Cancer
Review
作者: Wheatley, Carmen
ABSTRACT:
Background:
Supposed ‘spontaneous’ remissions in chronic lymphocytic leukaemia (CLL) are extremely rare. By the most stringent immunophenotypic criteria, there are only seven cases to date of unexplained, immune system effected cures. A historic review of this phenomenon is presented as context for this eighth case of CLL immunophenotypic reversal.
Case:
A 59‐year‐old, molecular biologist, stage I CLL, whose diagnosis and recovery were both thoroughly documented, not content to watch and wait, chose to treat himself, after individual tumour susceptibility testing, with evidence based, biological response modifiers, which initially seemed to keep his CLL stable. This included 1 mg of hydroxocobalamin injected i.m. daily. However, after some years his lymphocytosis began slowly to drift upwards. At that point, he was persuaded to change his injection protocol to methylcobalamin, at 50 mg i.m. a day, a dose whose clinical safety is sufficiently well‐established, and a form of cobalamin that the research literature shows has anticancer actions.
Conclusion:
This change in cobalamin form and dose proved a critical turning point. Complete disappearance of the lymphocytosis also coincided with a severe infection and an even further temporary increase of the parenteral methylcobalamin dose, both catalytic factors. In the 4th and 5th years following this, the patient's repeated immunophenotyping showed no clonal disease present. A brief review of the field of cobalamin in cancer research and treatment is given, with discussion of the various mechanisms by which cobalamins may impact on cancer/CLL. Historic analysis reveals that cyanocobalamin is generally cancer promotional, whereas hydroxocobalamin, methylcobalamin and adenosylcobalamin are cancer protective and cytotoxic. It is hypothesised that the actions of cobalamin in cancer aetiology and oncogenesis/progression are intertwined with those of nitric oxide, which tumours regulate to dupe the immune system to their presence, by causing a functional cobalamin deficiency in the host.
100 项与 甲钴胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肌萎缩侧索硬化 | 日本 | 2024-09-24 | |
| 周围神经系统疾病 | 日本 | 1987-04-16 | |
| 神经痛 | 中国 | - | |
| 神经炎 | 中国 | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 甲基丙二酸血症 | 临床前 | 美国 | 2024-10-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 130 | 築築糧鏇壓膚製窪淵選(積糧簾餘網構糧醖願艱) = 網窪餘簾壓築繭鏇觸鑰 襯積繭遞繭網鬱鹽餘觸 (繭網製網願鬱範網鬱鏇 ) | 积极 | 2022-05-09 | |||
Placebo | 築築糧鏇壓膚製窪淵選(積糧簾餘網構糧醖願艱) = 簾積範觸衊繭淵鏇廠襯 襯積繭遞繭網鬱鹽餘觸 (繭網製網願鬱範網鬱鏇 ) | ||||||
临床2期 | - | 網艱憲製醖觸鹽構鹹衊(憲鏇構積獵鹽窪糧獵願) = 選醖選選醖簾鏇構鑰繭 積糧餘顧遞願膚築構製 (淵壓衊夢淵艱築範獵製 ) | 积极 | 2021-07-19 | |||
網艱憲製醖觸鹽構鹹衊(憲鏇構積獵鹽窪糧獵願) = 醖顧憲網製艱齋繭鹽膚 積糧餘顧遞願膚築構製 (淵壓衊夢淵艱築範獵製 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用